Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
mRNA-1468 for Herpes Zoster Prevention in Healthy Adults >=50 Years
NCT05701800Phase 1Terminated
- Sponsor
- Moderna Inc
- Start
- Jan 2023
- Primary completion
- Dec 2025
- Modality
- Vaccines & Immunotherapeutics, Lipid-based Nanoparticles, mRNA Therapeutics
- Countries
- 2
01
Overview
Phase 1, randomised, single-blind trial of mRNA-1468 in herpes zoster (HZ) (8 arms), sponsored by Moderna Inc. Primary endpoints: Number Participants with Solicited Local and Systemic Reactogenicity Adverse Reactions, Number of Participants with Unsolicited Adverse Events (AEs) and 2 more. Started Jan 2023; status: terminated.
02
Drugs
mRNA-1468
03
Conditions
herpes zoster (HZ)
Beyond the preview
Go deeper on NCT05701800.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05701800.